Verrica Revenue Falls as Wart Treatment Sales Rise 58%

Verrica Pharmaceuticals Inc

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported a wider third-quarter loss and a 52% decline in total revenue as clinical development expenses increased, even as sales of its YCANTH skin treatment rose nearly 58% ahead of pivotal trial results that could expand the drug’s market.

The West Chester-based pharmaceutical company recorded a net loss of $12.4 million, or $0.58 per share, for the quarter ended September 30, 2026, compared with a loss of $300,000, or $0.03 per share, a year earlier.

Total revenue declined to $6.9 million from $14.3 million, primarily because the year-earlier period included a $10 million milestone payment from Japanese development partner Torii Pharmaceutical Co.

U.S. net product revenue from YCANTH, Verrica’s FDA-approved treatment for molluscum contagiosum, increased to a record $5.7 million from $3.6 million a year earlier. Sales rose 11.9% from the second quarter.

The increase reflected higher product deliveries to distribution partners and reduced spending on patient copay assistance.

YCANTH dispensed applicator units totaled 19,135, up approximately 36% from a year earlier but down 2.5% sequentially. Verrica attributed the quarterly decline to seasonal travel patterns affecting patients and providers.

READ:  Artesian Profit Falls as Utility Costs Outpace Revenue

The company is working to improve prescription fulfillment rates and insurance coverage as it expands YCANTH’s commercial distribution.

Research and development expenses increased to $7.6 million from $2.2 million, largely reflecting costs associated with the company’s Phase 3 clinical program evaluating YCANTH for common warts.

Verrica said Torii will fund the first $40 million of payments for the program, representing approximately 90% of currently estimated study costs.

Selling, general and administrative expenses increased to $10.4 million from $9.4 million.

The company completed enrollment in COVE-2, the first of two pivotal Phase 3 trials for common warts, in August. Enrollment in the second trial, COVE-3, has exceeded 50% of its current target.

Verrica expects topline results from COVE-2 in the first quarter of 2027, followed by COVE-3 results around midyear.

The trials could support an application to expand YCANTH’s approved uses into common warts, a condition Verrica estimates affects approximately 22 million Americans.

READ:  ArriVent Posts $133.5 Million Loss as Cancer Trial Falls Short

“Under our current operating plan, including finishing the global Phase 3 program in common warts, and the full utilization of our credit facility, we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program,” said Jayson Rieger, Verrica’s president and chief executive officer.

The company secured access to the remaining $15 million under a $27.5 million credit facility in October after meeting specified revenue, growth and operational milestones.

The financing arrangement is with an entity controlled by Paul B. Manning, Verrica’s chairman and largest shareholder. Management expects the available borrowing capacity to extend its cash runway into the fourth quarter of 2027.

That projection excludes potential clinical trial expenses associated with VP-315, an experimental cancer treatment the company is evaluating for patients with Gorlin syndrome.

The rare genetic disorder causes repeated development of basal cell carcinomas, potentially requiring numerous surgical procedures over a patient’s lifetime.

READ:  Solana Company Posts $105.2M Profit as Crypto Holdings Grow

Verrica is assessing a possible clinical study of VP-315 in that population using findings from its completed Phase 2 trial involving sporadic basal cell carcinoma.

The company also reported additional clinical analyses indicating that YCANTH-treated patients with molluscum contagiosum achieved complete clearance approximately four times faster than placebo recipients.

Internationally, Verrica is supporting a regulatory filing in Israel under a distribution and supply agreement with Medomie Pharma and supplying product for Torii’s YCANTH launch in Japan.

License and collaboration revenue totaled $1.2 million during the quarter, compared with $10.7 million a year earlier, when the Japanese partnership generated the $10 million milestone payment.

Verrica reported a non-GAAP net loss of $10.5 million, or $0.49 per share, compared with non-GAAP net income of $1.1 million, or $0.12 per share, in the third quarter of 2025.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.